Stroke Association's updated guidelines on the primary prevention of stroke, treatment of hypertension is among the most effective strategies for preventing both ischemic and hemorrhagic stroke. 4 Little is known, however, about the role of pulse wave velocity (PWV), a marker of arterial stiffness, in the primary prevention of stroke. There is a growing recognition that PWV may affect blood pressure (BP) and the response to antihypertension treatment. Large arterial stiffness and wave-reflection intensity have both been associated with Abstract-Pulse wave velocity (PWV) has been shown to influence the effects of antihypertensive drugs in the prevention of cardiovascular diseases. Data are limited on whether PWV is an independent predictor of stroke above and beyond hypertension control. This longitudinal analysis examined the independent and joint effect of brachial-ankle PWV (baPWV) with hypertension control on the risk of first stroke. This report included 3310 hypertensive adults, a subset of the China Stroke Primary Prevention Trial (CSPPT) with baseline measurements for baPWV. During a median follow-up of 4.5 years, 111 participants developed first stroke. The risk of stroke was higher among participants with baPWV in the highest quartile than among those in the lower quartiles (6.3% versus 2.4%; hazard ratio, 1.66; 95% confidence interval, 1.06-2.60). Similarly, the participants with inadequate hypertension control had a higher risk of stroke than those with adequate control (5.1% versus 1.8%; hazard ratio, 2.32; 95% confidence interval, 1.49-3.61). When baPWV and hypertension control were examined jointly, participants in the highest baPWV quartile and with inadequate hypertension control had the highest risk of stroke compared with their counterparts (7.5% versus 1.3%; hazard ratio, 3.57; 95% confidence interval, 1.88-6.77). There was a significant and independent effect of high baPWV on stroke as shown among participants with adequate hypertension control (4.2% versus 1.3%; hazard ratio, 2.29, 95% confidence interval, 1.09-4.81). In summary, among hypertensive patients, baPWV and hypertension control were found to independently and jointly affect the risk of first stroke. 6-8 Our previous study showed that baPWV was an independent determinant of individual response to antihypertensive treatment.
S
troke is the leading cause of death in China and the second leading cause of death in the world. 1 Primary prevention is regarded as the best option to reduce the population burden of stroke because ≈77% of strokes are first events. 2 Hypertension is a well-recognized major modifiable risk factor for stroke.
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isolated systolic hypertension. 5 Several studies have established an important relationship between PWV (either carotid-femoral PWV [cfPWV] or brachial-ankle PWV [baPWV] ) and BP progression. [6] [7] [8] Our previous study showed that baPWV was an independent determinant of individual response to antihypertensive treatment. 9 Particularly relevant to this report, recent longitudinal studies have demonstrated that increased baPWV levels predict cardiovascular mortality and morbidity among high-risk patients and the general population. [10] [11] [12] [13] In their current guidelines on the management of arterial hypertension, the European Society of Hypertension mentioned PWV as a potential consideration in managing middle-aged hypertensive patients with increased aortic stiffness.
14 However, none of the current stroke prevention guidelines have considered PWV because of limited data.
This study sought to investigate whether baPWV can, independently and jointly with hypertension control, affect the risk of incident stroke using data from the China Stroke Primary Prevention Trial (CSPPT). 15 We were particularly interested in whether baPWV has an additive value above and beyond hypertension control in predicting incident stroke risk.
Methods

Study Participants and Design
All participants were part of the CSPPT (clinicaltrials.gov identifier: NCT00794885). The CSPPT was approved by the ethics committee of the Institute of Biomedicine, Anhui Medical University, Hefei, China (FWA assurance number FWA00001263). All participants provided written informed consent.
A detailed description of the CSPPT can be found in a recent publication. 15 Briefly, the CSPPT was a multicommunity, randomized, double-blind, controlled trial conducted from May 2008 to August 2013 in 2 study centers in China (Jiangsu and Anhui provinces). It was designed to evaluate whether a combined therapy of enalapril plus folic acid is more effective than enalapril alone in reducing the risk of stroke in hypertensive patients. Eligible participants were men and women aged 45 to 75 years old who had hypertension, defined as seated resting systolic BP (SBP) ≥140 mm Hg or diastolic BP (DBP) ≥90 mm Hg at both the screening and the recruitment visit, or who were on antihypertensive medications. The major exclusion criteria included history of physician-diagnosed stroke, myocardial infarction, heart failure, postcoronary revascularization, or congenital heart disease.
Participants were scheduled for the first visit after a 3-week runin treatment period, and then were followed up every 3 months until completion of the trial. Each visit involved recording BP, pulse, treatment compliance, concomitant use of other medications, adverse events, and study outcome events.
Laboratory Tests
Overnight fasting venous blood samples were collected at the baseline. Laboratory tests were performed at the core laboratory of the National Clinical Research Center for Kidney Disease (Nanfang Hospital, Guangzhou, China). Fasting plasma glucose (FPG), fasting lipids (serum total cholesterol, high-density lipoprotein-cholesterol, and triglycerides), serum homocysteine, and creatinine were measured using automatic clinical analyzers (Beckman Coulter). An ABI Prism 7900HT sequence detection system (Life Technologies) was used to detect MTHFR gene C677T polymorphisms (MTHFR: methylenetetrahydrofolate reductase is the main regulatory enzyme for folate metabolism). Serum folate and vitamin B 12 were measured at baseline by a commercial laboratory using a chemiluminescent immunoassay (New Industrial).
BaPWV Measurements
BaPWV, calculated as the ratio of transmission distance from the brachium to the ankle divided by the transit time, was used in this study. Participants were asked to remain in the supine position for at least 5 minutes after which baseline baPWV was measured using an automatic waveform analyzer (form PWV/ABI, BP-203RPE; OmronColin, Japan) according to published guidelines. 9, 16 Examinations were performed on both the left and right sides. Four oscillometric cuffs were applied to bilateral brachia and ankles, and ECG electrodes were placed on bilateral wrists. The cuffs were connected to a plethysmographic sensor that determines volume pulse-form and to an oscillometric pressure sensor that measures BP. Both cuffs were simultaneously pressurized to approximate the patient's diastolic pressure while the pulse volume waveforms were recorded using semiconductor pressure sensors. The distance between sampling points of baPWV was calculated automatically according to the height of the patient. The path length from the suprasternal notch to the ankle (La) was obtained using the following equation: La=0.8129×height (cm)+12.328. The path length from the suprasternal notch to the brachium (Lb) was obtained using the following equation: Lb=0.2195×height (cm)−2.0734. The baPWV was calculated according to the following formula: baPWV=(La−Lb)/ Tba, where Tba was the time interval between the wavefront of the brachial waveform and that of the ankle waveform. Simultaneous, bilateral readings of baPWV were measured twice, and the maximum reading from each side was used for the analysis. BaPWV was analyzed as quartiles and as a dichotomized variable: Q1-Q3 versus Q4, in accordance with previous literature.
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BP Measurements
SBP/DBP (mm Hg) was measured at the baseline and at each followup visit with the subject in the sitting position after having rested for more than 5 minutes, and using a mercury sphygmomanometer with an appropriate cuff size. Three consecutive measurements were obtained on the right arm, with 1-minute intervals between each, and the mean value was calculated. Subjects were grouped according to whether hypertension was controlled: yes (mean SBP<140 and DBP<90 mm Hg) or no (mean SBP≥140 and/or DBP≥90 mm Hg).
Outcome Assessment
The primary outcome of interest was first incident nonfatal or fatal stroke (ischemic or hemorrhagic) occurring between baseline and follow-up (a median of 4.5 years), excluding subarachnoid hemorrhage and silent stroke. As detailed in a recent report, all stroke cases were adjudicated by experts of the End Point Adjudication Committee using predefined criteria. 15 More details on stroke definition and event adjudication can be found in their CSPPT online appendix.
Statistical Analysis
Data were analyzed using the statistical package R (http://www. r-project.org) and Empower (R) (www.empowerstats.com; X&Y Solutions, Inc., Boston, MA). Data are presented as mean±SD for continuous variables and as frequency (%) for categorical variables. In all analyses, variables with a non-normal distribution were logtransformed before analysis. The population characteristics of the different groups were compared using 2-sample t tests, signed-rank tests, or χ 2 tests, accordingly. The effects of baPWV and hypertension control status on first stroke were evaluated using Kaplan-Meier curves (log-rank test) and Cox proportional hazards models (hazards ratio [HR] and 95% confidence interval [CI]) with adjustment for major covariables including age, sex, study center, treatment group, body mass index (BMI), smoking status, alcohol consumption, baseline SBP and DBP, total cholesterol, high-density lipoproteincholesterol, triglycerides, FPG, creatinine, B 12 , folate, homocysteine, and MTHFR C677T polymorphisms. Several sensitivity tests were performed by including various sets of appropriate covariates in the models based on evidence from published literature and biological plausibility as well as those that displayed evidence of collinearity. A 2-tailed P<0.05 was considered to be statistically significant.
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Characteristics of the study participants included and excluded from this present study are listed in Table S1 in the online-only Data Supplement. The majority of the CSPPT participants had estimated glomerular filtration rate (eGFR) within the normal range (>90 mL/ min per 1.73 m 2 ) at baseline. Baseline eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. 18 There was a small fraction of participants with eGFR <60 (mL/min per 1.73 m 2 ), but none had a history of dialysis. As shown in Tables  S2 and S3 , when additional analyses were performed by adjusting either creatinine or eGFR, the results were similar to those found without adjusting for eGFR and creatinine.
We also analyzed the effect of PWV normalized for BP: PWVnorm=100×(PWV/meanBP) and found patterns of association that were similar to those for baPWV (Tables S4 and S5 ).
19
Results
The present study included 3310 participants, a subset of the CSPPT, with baPWV measured at baseline. The mean (SD) age of the participants was 59.6 (7.5) years; 1456 were men (44%). Mean baseline baPWV was 18.76 (±SD 3.82) m/s. The characteristics of the participants are presented in Table 1 . Compared with participants with baPWV in the lower quartiles (Q1-Q3), participants with baPWV in the highest quartile (Q4) had a higher mean age and heart rate, higher levels of FPG, total cholesterol, high-density lipoprotein-cholesterol levels, homocysteine, and BP at baseline and over the treatment period, and lower BMI. No significant differences were found between the 2 groups in terms of triglycerides, creatinine, folate, vitamin B 12 , MTHFR genotype distribution, alcohol consumption, smoking status, or treatment group.
Compared with participants with adequate hypertension control (SBP<140 and DBP<90 mm Hg) over the treatment period, participants with inadequately controlled hypertension (SBP≥140 and/or DBP≥90 mm Hg) had higher levels of BMI, FPG, triglycerides, baPWV, and SBP/DBP at baseline and over the follow-up period.
During a median follow-up of 4.5 years, there were 111 total incident strokes including 96 ischemic strokes and 15 hemorrhagic strokes. The risk of stroke was higher among participants with baPWV in the highest quartile than among those with levels in the lower quartiles (6.3% versus 2.4%); a similar pattern (5.1% versus 1.8%) was found among participants with inadequate hypertension control compared to those with adequate control (mean SBP<140 and DBP<90 mm Hg).
In Table 2 , Cox regression analysis was used to estimate the individual effect of baPWV and hypertension control on incident stroke risk. Higher baPWV (in the fourth quartile) was associated with a greater risk of incident stroke compared with baPWV in the lower quartiles (Q1-Q3): the HR was 2.69 (95% CI, 1.86, 3.91; P<0.001) in the crude model and 1.66 (95% CI, 1.06, 2.60; P=0.027) in the multivariate model with adjustment for age, sex, center, treatment regimen, BMI, smoking status, alcohol consumption, baseline SBP and DBP, total cholesterol, high-density lipoprotein-cholesterol, triglycerides, FPG, creatinine, vitamin B 12 , folate, homocysteine, and MTHFR C677T polymorphism. There were no significant interactions between baPWV and any of these covariates (P>0.05 for all interactions; data not shown).
When baPWV and hypertension control were examined together, the Kaplan-Meyer curves (Figure 1) showed that the cumulative hazard of stroke significantly differed among the 4 groups defined by baPWV and hypertension control categories (comparing baPWV in the fourth and lower quartiles among those participants with uncontrolled hypertension, the P=0.001; comparing baPWV in the fourth and lower quartiles among those participants with controlled hypertension, the P=0.0025.).
As shown in Figure 2 , within each stratum of hypertension control, there was a positive relationship between quartiles of baPWV and risk of stroke. However, the overall risk was higher among the stratum of inadequate hypertension control.
The Cox proportional hazards regression analyses (Table 3 ) estimated that the highest risk of stroke was in the group with high baPWV and inadequate hypertension control, with an HR of 3.6 (95% CI, 1.9-6.8; P<0.001) after adjusting for pertinent demographic and cardiovascular risk factors. The analyses revealed an additive effect of increased baPWV and inadequate hypertension control on stroke risk. An independent effect of high baPWV on stroke was clearly seen among participants with adequate hypertension control (HR, 2.3, 95% CI, 1.1-4.8; P=0.029).
Discussion
This study lends further support to the growing literature pointing to PWV as an independent predictor of cardiovascular disease. 20 Several studies have revealed a clear relationship between PWV (either cfPWV or baPWV) and cardiovascular disease in hypertensive patients. A study by Laurent et al 10 found that aortic stiffness is an independent predictor of allcause and cardiovascular mortality in patients with essential hypertension, independent of other risk factors such as diabetes mellitus and age. More recently, studies have shown an association between PWV increase and cardiovascular complications in patients with hypertension. [21] [22] [23] This study has contributed the following new insights. To date, there is a particular lack of data on the role of PWV on first stroke. A longitudinal study by Laurent et al 10 first showed that aortic stiffness is a predictor of fatal stroke in essential hypertension patients, with a relative risk (RR) increase of 1.72 for each SD increase in PWV (4 m/s). 24 We demonstrated an independent effect of high baPWV on incident stroke among participants with adequate hypertension control (HR, 2.3; 95% CI, 1.1-4.8; P=0.029). To our knowledge, our study is the first to examine the independent and joint effect of baPWV and hypertension control on the risk of first stroke among hypertensive adults. Our data clearly showed the additive value of PWV above and beyond hypertension control in predicting incident stroke risk.
Our study findings have important clinical and public health implications. In their current guidelines on the management of arterial hypertension, the European Society of Hypertension included PWV as a potential consideration in managing middle-aged hypertensive patients with increased aortic stiffness.
14 To date, none of the current stroke prevention guidelines in the United States, Europe, or China have considered PWV as a predictor in risk assessment or as a target for prevention of stroke because of limited data. Our findings raise the possibility that baPWV measurement may serve as a simple noninvasive measurement to help identify hypertensive adults who are at high risk for stroke, and as a novel therapeutic target in stroke prevention. Whether baPWV exhibits a threshold effect, and if so, whether the threshold varies by population and health conditions remain to be determined. The predictive value of baPWV in cardiovascular events has also been reported in high-risk populations including patients with chronic hemodialysis, acute coronary syndrome, diabetes mellitus with coronary artery disease, and heart failure, with increased risk threshold values of 18 to 19.6, 18, 17.3, and 17.5 m/s, respectively. [25] [26] [27] [28] [29] The Japanese Circulation Society has proposed a baPWV of 18 m/s as the threshold for high risk. 30 Our data appear to support a threshold of ≈20 m/s. On the contrary, a meta-analysis of 12 cohort studies confirmed that baPWV is an independent predictor for cardiovascular disease onset and found an increase of 1 m/s to be associated with a 12% increase in the risk of cardiovascular events. 12 Although cfPWV is the "gold standard" for measuring aortic stiffness, baPWV correlates well with cfPWV, with a correlation coefficient range of 0.75 to 0.87, and seems to HR estimated using the Cox proportional hazards model. P value derived from the log-rank test. Model I: adjusted for age, sex, center, treatment group, body mass index, smoking status, and alcohol consumption; model II: all of the variables in model I plus baseline SBP and DBP, total cholesterol, high-density lipoproteincholesterol, triglycerides, fasting plasma glucose, creatinine, B 12 , folate, homocysteine and MTHFR C677T polymorphism. baPWV indicates brachial-ankle pulse wave velocity; CI, confidence interval; DBP, diastolic blood pressure; HR, hazard ratio; IQR, interquartile range; and SBP, systolic blood pressure. be more representative than cfPWV of arterial load. [31] [32] [33] [34] One published validation study of baPWV demonstrated both validity and reproducibility of baPWV when compared with aortic PWV. 35 The utility of baPWV versus cfPWV in stroke risk assessment is worth mentioning. Theoretically, cfPWV reflects mainly central arterial stiffness, whereas baPWV reflects both central and peripheral arterial stiffness. A review has shown that the brachial measure is predictive of cardiovascular disease. 20 Previous studies have also shown that, compared with cfPWV, baPWV is more strongly related to cardiovascular risk factors and displays stronger associations with the presence of coronary calcium and left ventricular mass. 34, 36, 37 BaPWV is particularly attractive for preventive screening, as it is not time consuming to measure, does not involve manipulation of the femoral artery area, and has good reproducibility without requiring a highly skilled technician.
Interestingly, we identified a moderate inverse relationship between BMI and baPWV, which may be because of the characteristics of our study participants: the majority of them (≈80%) were farmers. We suspect that BMI in this population may reflect muscle mass and physical activity rather than adiposity.
The causes of increased arterial stiffness and strategies to reduce it warrant additional studies. BaPWV increases with age, hypertension, or diabetes mellitus, and is associated with more advanced organ damage. After menopause, baPWV increases rapidly, and the sex difference disappears after the age of 60 years. [38] [39] [40] [41] We suspect that a better understanding of the causes and biological mechanisms for increased arterial stiffness may help improve our ability to predict and prevent stroke.
Our study has some limitations. The CSPPT participants were predominantly rural Chinese, thus the generalizability of our findings to other populations requires caution. The sample size of our study was modest in terms of the number of incident stroke cases; additional large longitudinal studies in diverse settings are needed to confirm our study findings. Arterial stiffness is probably related to atherosclerosis and is expected to be a stronger predictor of large artery stroke than of small vessel stroke. Unfortunately, we were unable to differentiate small-versus large-vessel stroke in our study.
Perspectives
In this prospective analysis of Chinese adults with hypertension, baseline baPWV and hypertension control status over the 4.5-year treatment period independently and jointly affected the risk of incident stroke. We speculate that interventions aiming to simultaneously control these risk factors may be more effective in reducing arterial stiffness and preventing adverse cerebrovascular events than hypertension control alone. The study raises the possibility that baPWV may serve baPWV indicates brachial-ankle pulse wave velocity; CI, confidence interval; and HR, hazard ratio. HR estimated using the Cox proportional hazards model. P value derived from the log-rank test. Model I: adjusted for age, sex, center, treatment group, body mass index, smoking status, and alcohol consumption; model II: all of the variables in Model I plus baseline systolic blood pressure and diastolic blood pressure, total cholesterol, high-density lipoprotein-cholesterol, triglycerides, fasting plasma glucose, creatinine, B 12 , folate, homocysteine, and MTHFR C677T polymorphism. Table S1 . Baseline and follow-up characteristics of the study participants included and excluded from this present study, all of them were part of the CSPPT study (overall N= 20702 participants). Table S2 . Individual effect of baseline baPWV and blood pressure control on incident stroke. Table S3 . Joint effects of baseline baPWV levels (Q1-Q3 vs. Q4) and status of blood pressure control (yes, no) on incident stroke. Table S4 . Individual effect of baseline baPWV normalized for blood pressure [PWVnorm = 100 × (PWV/MBP)] and blood pressure control on incident stroke. Table S5 . Joint effects of baseline baPWV normalized for blood pressure levels (Q1-Q3 vs. Q4) [PWVnorm = 100 × (PWV/MBP)] and status of blood pressure control (yes, no) on incident stroke. Table S1 . Baseline and follow-up characteristics of the study participants included and excluded from this present study, all of them were part of the CSPPT study ( Abbreviations: CI, confidence interval; HR, hazard ratio. HR estimated using the Cox proportional hazards model. P-value derived from the logrank test.
